聚乙二醇脂质体阿霉素：在卵巢上皮性癌治疗中的当前作用评价。
Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer.
机构信息
Cancer Treatment Centers of America, Eastern Regional Medical Center, Philadelphia, PA, USA.
出版信息
Cancer Manag Res. 2011;3:219-25. doi: 10.2147/CMR.S15558. Epub 2011 Jun 13.
Abstract
Pegylated liposomal doxorubicin (PLD) has become a major component in the routine management of epithelial ovarian cancer. The drug is frequently employed as a single agent in the platinum-resistant setting, and recently reported data reveal the superiority of the combination of PLD plus carboplatin, compared with the platinum drug plus paclitaxel, in delaying the time to disease progression in women with recurrent (potentially platinum-sensitive) disease. Current research efforts involving PLD in ovarian cancer are focusing on adding novel targeted drugs to this cytotoxic agent. The utility of such approaches in the platinum-resistant population, compared with the sequential administration of single agents active in this setting, remains to be determined.
摘要
聚乙二醇脂质体阿霉素（PLD）已成为上皮性卵巢癌常规治疗的重要组成部分。该药常作为单一药物用于铂耐药患者，最近报道的数据显示，PLD 联合卡铂与铂类药物联合紫杉醇相比，可延迟铂敏感复发患者的疾病进展时间。目前针对卵巢癌的 PLD 相关研究主要集中在将新型靶向药物与这种细胞毒性药物联合应用。与该治疗环境中单药序贯治疗相比，这种方法在铂耐药人群中的应用价值仍有待确定。
相似文献
1
Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer.
Cancer Manag Res. 2011;3:219-25. doi: 10.2147/CMR.S15558. Epub 2011 Jun 13.
2
Clinical trials with pegylated liposomal Doxorubicin in the treatment of ovarian cancer.
J Drug Deliv. 2013;2013:898146. doi: 10.1155/2013/898146. Epub 2013 Mar 14.
3
Optimal chemotherapy treatment for women with recurrent ovarian cancer.
Curr Oncol. 2007 Oct;14(5):195-208. doi: 10.3747/co.2007.148.
4
Pegylated liposomal doxorubicin/carboplatin combination in ovarian cancer, progressing on single-agent pegylated liposomal doxorubicin.
World J Clin Oncol. 2012 Oct 10;3(10):137-41. doi: 10.5306/wjco.v3.i10.137.
5
Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer.
Cochrane Database Syst Rev. 2013 Oct 21;2013(10):CD010482. doi: 10.1002/14651858.CD010482.pub2.
6
Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer.
Gynecol Oncol. 2016 Feb;140(2):210-4. doi: 10.1016/j.ygyno.2015.11.031. Epub 2015 Nov 28.
7
Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200).
Gynecol Oncol. 2008 Jan;108(1):90-4. doi: 10.1016/j.ygyno.2007.08.075. Epub 2007 Oct 18.
8
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
Eur J Cancer. 2015 Feb;51(3):352-8. doi: 10.1016/j.ejca.2014.11.017. Epub 2014 Dec 17.
9
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
J Clin Oncol. 2010 Jul 10;28(20):3323-9. doi: 10.1200/JCO.2009.25.7519. Epub 2010 May 24.
10
[Pegylated liposomal doxorubicin in ovarian cancer treatment].
Ginekol Pol. 2009 Aug;80(8):615-9.
引用本文的文献
1
Tap the sap - investigation of latex-bearing plants in the search of potential anticancer biopharmaceuticals.
Front Plant Sci. 2022 Nov 1;13:979678. doi: 10.3389/fpls.2022.979678. eCollection 2022.
2
A Novel, Personalized Drug-Screening System for Platinum-Resistant Ovarian Cancer Patients: A Preliminary Clinical Report.
Cancer Manag Res. 2021 Mar 29;13:2849-2867. doi: 10.2147/CMAR.S276799. eCollection 2021.
3
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer.
J Ovarian Res. 2021 Jan 11;14(1):12. doi: 10.1186/s13048-020-00736-2.
4
Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers.
Curr Treat Options Cardiovasc Med. 2018 Mar 1;20(2):18. doi: 10.1007/s11936-018-0609-z.
5
Non-pegylated liposomal doxorubicin for patients with recurrent ovarian cancer: A multicentric phase II trial.
Oncol Lett. 2016 Aug;12(2):1211-1215. doi: 10.3892/ol.2016.4740. Epub 2016 Jun 16.
6
A novel PEGylated liposome-encapsulated SANT75 suppresses tumor growth through inhibiting hedgehog signaling pathway.
PLoS One. 2013;8(4):e60266. doi: 10.1371/journal.pone.0060266. Epub 2013 Apr 1.
7
Dual targeting strategies with bispecific antibodies.
MAbs. 2012 Mar-Apr;4(2):182-97. doi: 10.4161/mabs.4.2.19000. Epub 2012 Mar 1.
8
Sterically stabilized liposomes incorporating the novel anticancer agent phospho-ibuprofen (MDC-917): preparation, characterization, and in vitro/in vivo evaluation.
Pharm Res. 2012 Jun;29(6):1435-43. doi: 10.1007/s11095-011-0619-y. Epub 2011 Nov 10.
本文引用的文献
1
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial.
J Clin Oncol. 2011 Sep 20;29(27):3628-35. doi: 10.1200/JCO.2010.33.8566. Epub 2011 Aug 15.
2
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.
N Engl J Med. 2010 Sep 2;363(10):943-53. doi: 10.1056/NEJMoa0908806.
3
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.
J Clin Oncol. 2010 Jul 1;28(19):3107-14. doi: 10.1200/JCO.2009.25.4037. Epub 2010 Jun 1.
4
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
J Clin Oncol. 2010 Jul 10;28(20):3323-9. doi: 10.1200/JCO.2009.25.7519. Epub 2010 May 24.
5
Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.
Gynecol Oncol. 2010 Mar;116(3):323-5. doi: 10.1016/j.ygyno.2009.11.026. Epub 2009 Dec 30.
6
Ovarian cancer.
Lancet. 2009 Oct 17;374(9698):1371-82. doi: 10.1016/S0140-6736(09)61338-6. Epub 2009 Sep 28.
7
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.
Lancet. 2009 Oct 17;374(9698):1331-8. doi: 10.1016/S0140-6736(09)61157-0. Epub 2009 Sep 18.
8
Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer.
Eur J Cancer. 2009 Sep;45(13):2324-32. doi: 10.1016/j.ejca.2009.05.016. Epub 2009 Jun 8.
9
Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
Gynecol Oncol. 2009 Aug;114(2):219-24. doi: 10.1016/j.ygyno.2009.04.007. Epub 2009 May 17.
10
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.
J Clin Oncol. 2009 Mar 20;27(9):1419-25. doi: 10.1200/JCO.2008.19.1684. Epub 2009 Feb 17.
Zotero 插件